RVL Pharmaceuticals Statistics
Total Valuation
RVL Pharmaceuticals has a market cap or net worth of 111. The enterprise value is 38.99 million.
Market Cap | 111 |
Enterprise Value | 38.99M |
Important Dates
The next estimated earnings date is Tuesday, March 25, 2025.
Earnings Date | Mar 25, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RVL Pharmaceuticals has 111.41 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 111.41M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +0.05% |
Owned by Insiders (%) | 2.76% |
Owned by Institutions (%) | n/a |
Float | 96.50M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 0.00 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.57 |
EV / Sales | 1.06 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.82 |
Financial Position
The company has a current ratio of 0.38, with a Debt / Equity ratio of 3.56.
Current Ratio | 0.38 |
Quick Ratio | 0.31 |
Debt / Equity | 3.56 |
Debt / EBITDA | n/a |
Debt / FCF | -1.22 |
Interest Coverage | -33.53 |
Financial Efficiency
Return on equity (ROE) is -182.44% and return on invested capital (ROIC) is -28.03%.
Return on Equity (ROE) | -182.44% |
Return on Assets (ROA) | -23.65% |
Return on Capital (ROIC) | -28.03% |
Revenue Per Employee | 295,352 |
Profits Per Employee | -546,128 |
Employee Count | 125 |
Asset Turnover | 0.35 |
Inventory Turnover | 6.93 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.83% in the last 52 weeks. The beta is 26.78, so RVL Pharmaceuticals's price volatility has been higher than the market average.
Beta (5Y) | 26.78 |
52-Week Price Change | -95.83% |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 48.01 |
Average Volume (20 Days) | 33,920 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.14 |
Income Statement
In the last 12 months, RVL Pharmaceuticals had revenue of 36.92 million and -68.27 million in losses. Loss per share was -0.70.
Revenue | 36.92M |
Gross Profit | 30.39M |
Operating Income | -39.77M |
Pretax Income | -68.54M |
Net Income | -68.27M |
EBITDA | -39.39M |
EBIT | -39.77M |
Loss Per Share | -0.70 |
Balance Sheet
The company has 19.16 million in cash and 58.15 million in debt, giving a net cash position of -38.99 million or -0.35 per share.
Cash & Cash Equivalents | 19.16M |
Total Debt | 58.15M |
Net Cash | -38.99M |
Net Cash Per Share | -0.35 |
Equity (Book Value) | 16.33M |
Book Value Per Share | 0.16 |
Working Capital | -42.64M |
Cash Flow
In the last 12 months, operating cash flow was -44.41 million and capital expenditures -3.08 million, giving a free cash flow of -47.49 million.
Operating Cash Flow | -44.41M |
Capital Expenditures | -3.08M |
Free Cash Flow | -47.49M |
FCF Per Share | -0.43 |
Margins
Gross margin is 82.31%, with operating and profit margins of -107.73% and -184.91%.
Gross Margin | 82.31% |
Operating Margin | -107.73% |
Pretax Margin | -185.66% |
Profit Margin | -184.91% |
EBITDA Margin | -106.69% |
EBIT Margin | -107.73% |
FCF Margin | n/a |
Dividends & Yields
RVL Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -25.65% |
Shareholder Yield | -25.65% |
Earnings Yield | -69,871,200.00% |
FCF Yield | -42,623,361.10% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RVL Pharmaceuticals has an Altman Z-Score of -10.42. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -10.42 |
Piotroski F-Score | n/a |